320 related articles for article (PubMed ID: 14579523)
1. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
2. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
4. SRC inhibitors in metastatic bone disease.
Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
7. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.
Shakespeare W; Yang M; Bohacek R; Cerasoli F; Stebbins K; Sundaramoorthi R; Azimioara M; Vu C; Pradeepan S; Metcalf C; Haraldson C; Merry T; Dalgarno D; Narula S; Hatada M; Lu X; van Schravendijk MR; Adams S; Violette S; Smith J; Guan W; Bartlett C; Herson J; Iuliucci J; Weigele M; Sawyer T
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9373-8. PubMed ID: 10944210
[TBL] [Abstract][Full Text] [Related]
10. Future anti-catabolic therapeutic targets in bone disease.
Boyce BF; Xing L; Yao Z; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Ann N Y Acad Sci; 2006 Apr; 1068():447-57. PubMed ID: 16831942
[TBL] [Abstract][Full Text] [Related]
11. Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Metcalf CA; van Schravendijk MR; Dalgarno DC; Sawyer TK
Curr Pharm Des; 2002; 8(23):2049-75. PubMed ID: 12171518
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
14. The potential role of bisphosphonates in prostate cancer.
Oades GM; Coxon J; Colston KW
Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
[TBL] [Abstract][Full Text] [Related]
15. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
16. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M
Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening of Src kinase inhibitors.
Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
